JP2014533701A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533701A5 JP2014533701A5 JP2014542590A JP2014542590A JP2014533701A5 JP 2014533701 A5 JP2014533701 A5 JP 2014533701A5 JP 2014542590 A JP2014542590 A JP 2014542590A JP 2014542590 A JP2014542590 A JP 2014542590A JP 2014533701 A5 JP2014533701 A5 JP 2014533701A5
- Authority
- JP
- Japan
- Prior art keywords
- cysteamine
- cystamine
- derivative
- composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 30
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 24
- 102100031786 Adiponectin Human genes 0.000 claims 15
- 108010076365 Adiponectin Proteins 0.000 claims 15
- 229960003151 mercaptamine Drugs 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 229940099500 cystamine Drugs 0.000 claims 13
- 208000007536 Thrombosis Diseases 0.000 claims 11
- 208000037906 ischaemic injury Diseases 0.000 claims 9
- 230000000302 ischemic effect Effects 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 5
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 4
- 206010064571 Gene mutation Diseases 0.000 claims 4
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000007056 sickle cell anemia Diseases 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 238000013270 controlled release Methods 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 3
- 201000005657 Antithrombin III deficiency Diseases 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 206010058279 Factor V Leiden mutation Diseases 0.000 claims 2
- 208000033892 Hyperhomocysteinemia Diseases 0.000 claims 2
- 201000005660 Protein C Deficiency Diseases 0.000 claims 2
- 206010051292 Protein S Deficiency Diseases 0.000 claims 2
- 108010094028 Prothrombin Proteins 0.000 claims 2
- 102100027378 Prothrombin Human genes 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000003429 anti-cardiolipin effect Effects 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000033666 hereditary antithrombin deficiency Diseases 0.000 claims 2
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims 2
- 230000003225 hyperhomocysteinemia Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 229940039716 prothrombin Drugs 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 201000005665 thrombophilia Diseases 0.000 claims 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- VXIXUWQIVKSKSA-UHFFFAOYSA-N 4-hydroxycoumarin Chemical class C1=CC=CC2=C1OC(=O)C=C2O VXIXUWQIVKSKSA-UHFFFAOYSA-N 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 208000014882 Carotid artery disease Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010051151 Hyperviscosity syndrome Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 108010023197 Streptokinase Proteins 0.000 claims 1
- 108010039185 Tenecteplase Proteins 0.000 claims 1
- 208000026062 Tissue disease Diseases 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 229960002054 acenocoumarol Drugs 0.000 claims 1
- VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960003318 alteplase Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 230000010100 anticoagulation Effects 0.000 claims 1
- 229960003856 argatroban Drugs 0.000 claims 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000000039 congener Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 claims 1
- 229960001912 dicoumarol Drugs 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 239000002117 illicit drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940127234 oral contraceptive Drugs 0.000 claims 1
- 239000003539 oral contraceptive agent Substances 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 claims 1
- 229960002917 reteplase Drugs 0.000 claims 1
- 108010051412 reteplase Proteins 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229960005202 streptokinase Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229960000216 tenecteplase Drugs 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
- 229940019333 vitamin k antagonists Drugs 0.000 claims 1
- 229960005080 warfarin Drugs 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563034P | 2011-11-22 | 2011-11-22 | |
| US61/563,034 | 2011-11-22 | ||
| PCT/US2012/066288 WO2013078335A1 (en) | 2011-11-22 | 2012-11-21 | Cysteamine and/or cystamine for treating ischemic injury |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533701A JP2014533701A (ja) | 2014-12-15 |
| JP2014533701A5 true JP2014533701A5 (enExample) | 2016-01-21 |
| JP6411215B2 JP6411215B2 (ja) | 2018-10-24 |
Family
ID=47297472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542590A Expired - Fee Related JP6411215B2 (ja) | 2011-11-22 | 2012-11-21 | 虚血傷害を治療するためのシステアミンおよび／またはシスタミン |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140322315A1 (enExample) |
| EP (1) | EP2782564B1 (enExample) |
| JP (1) | JP6411215B2 (enExample) |
| KR (1) | KR20140097132A (enExample) |
| CN (2) | CN103974698A (enExample) |
| AU (1) | AU2012340670B2 (enExample) |
| BR (1) | BR112014012167A2 (enExample) |
| CA (1) | CA2851387A1 (enExample) |
| HK (1) | HK1202440A1 (enExample) |
| IL (1) | IL232608A0 (enExample) |
| MX (1) | MX2014004469A (enExample) |
| MY (1) | MY165953A (enExample) |
| RU (1) | RU2638807C2 (enExample) |
| SG (2) | SG11201402472QA (enExample) |
| WO (1) | WO2013078335A1 (enExample) |
| ZA (1) | ZA201402290B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR096628A1 (es) * | 2013-06-17 | 2016-01-20 | Raptor Pharmaceuticals Inc | Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella |
| TWI759267B (zh) | 2015-07-02 | 2022-04-01 | 美商地平線罕見醫學製藥有限責任公司 | Ａｄｏ抗性半胱胺類似物及其用途 |
| CN106591461A (zh) * | 2016-12-29 | 2017-04-26 | 天津协和华美医学诊断技术有限公司 | 一种检测遗传性易栓症相关基因群的检测试剂盒 |
| CN110392568A (zh) | 2017-01-19 | 2019-10-29 | 耳科制药公司 | N-乙酰半胱氨酸的制剂及其用途 |
| MX2019008847A (es) * | 2017-01-25 | 2019-12-16 | Adare Pharmaceuticals Inc | Profarmacos de cisteamina. |
| WO2021022012A1 (en) * | 2019-07-30 | 2021-02-04 | The Regents Of The University Of California | Methods and composition for treating respiratory obstructive diseases |
| CN113484453B (zh) * | 2021-07-07 | 2022-08-09 | 天津中医药大学 | 一种缺血性脑卒中预警方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
| FR2471186A1 (fr) | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| US4301146A (en) | 1980-07-29 | 1981-11-17 | G. D. Searle & Co. | Stabilization of 16-oxygenated prostanoic acid derivatives |
| FR2549051B1 (fr) | 1983-06-22 | 1986-05-16 | Centre Nat Rech Scient | Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation |
| FR2573077B1 (fr) * | 1984-11-13 | 1987-02-13 | Sanofi Sa | Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| KR890004692A (ko) * | 1987-09-08 | 1989-05-09 | 스야마 타다카즈 | 혈소판 응지억제제 |
| JPH02243619A (ja) * | 1989-03-15 | 1990-09-27 | Green Cross Corp:The | 抗血小板凝集剤 |
| SK232890A3 (en) | 1989-05-17 | 1998-11-04 | Pfizer | 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof |
| US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
| US5436255A (en) | 1992-07-23 | 1995-07-25 | Pfizer Inc. | Method of treating diseases susceptable to treatment by blocking NMDA-receptors |
| TW281670B (enExample) | 1993-09-02 | 1996-07-21 | Hoffmann La Roche | |
| ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| ZA9610736B (en) | 1995-12-22 | 1997-06-27 | Warner Lambert Co | 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists |
| WO1997023202A1 (en) | 1995-12-22 | 1997-07-03 | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON | Subtype-selective nmda receptor ligands and the use thereof |
| ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| US6087398A (en) * | 1996-03-01 | 2000-07-11 | South Alabama Medical Science Foundation | Sickle cell anemia treatment |
| FR2753098B1 (fr) * | 1996-09-06 | 1998-11-27 | Sod Conseils Rech Applic | Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene |
| DE19643790A1 (de) | 1996-10-30 | 1998-05-07 | Merck Patent Gmbh | Benzoxazol-Derivat |
| NZ502785A (en) | 1997-10-24 | 2003-03-28 | Warner Lambert Co | Use of NR1A/2B site-selective NMDA receptor antagonist compounds for treating disease-related or drug-induced dyskinesias |
| PE20000728A1 (es) | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
| AU1808100A (en) | 1998-10-28 | 2000-05-15 | Vitaly V. Romanenko | Electrodynamic particle size analyzer |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| US6316474B1 (en) | 1999-10-29 | 2001-11-13 | Merck & Co., Inc. | 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists |
| US6432976B1 (en) | 1999-10-29 | 2002-08-13 | Merck & Co., Inc. | 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists |
| WO2001030330A2 (en) | 1999-10-29 | 2001-05-03 | Merck Sharp & Dohme Limited | Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
| US6369076B1 (en) | 1999-10-29 | 2002-04-09 | Merck & Co. Inc. | 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists |
| US6489477B1 (en) | 1999-10-29 | 2002-12-03 | Merck & Co., Inc. | 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists |
| US6291499B1 (en) | 1999-10-29 | 2001-09-18 | Merck & Co., Inc. | 2-cyclohexyl benzimidazole NMDA/NR2B antagonists |
| ATE515261T1 (de) * | 2003-12-19 | 2011-07-15 | Omega Bio Pharma Ip3 Ltd | Zusammensetzungen zur behandlung von diabetes |
| CN1976691B (zh) * | 2004-05-03 | 2010-10-13 | 奥加生物药业(I.P.3)有限公司 | 半胱胺用于治疗高胆固醇血症和糖尿病并发症 |
| EP2214480B1 (en) * | 2007-11-30 | 2013-03-27 | The Regents of the University of California | Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products |
| RU2428192C1 (ru) * | 2010-06-10 | 2011-09-10 | Войсковая Часть 41598 | Радиозащитное средство |
-
2012
- 2012-11-21 SG SG11201402472QA patent/SG11201402472QA/en unknown
- 2012-11-21 CN CN201280057439.7A patent/CN103974698A/zh active Pending
- 2012-11-21 RU RU2014125282A patent/RU2638807C2/ru not_active IP Right Cessation
- 2012-11-21 CN CN201810067673.7A patent/CN108042517A/zh active Pending
- 2012-11-21 HK HK15103104.0A patent/HK1202440A1/xx unknown
- 2012-11-21 JP JP2014542590A patent/JP6411215B2/ja not_active Expired - Fee Related
- 2012-11-21 BR BR112014012167A patent/BR112014012167A2/pt not_active IP Right Cessation
- 2012-11-21 EP EP12798116.5A patent/EP2782564B1/en not_active Not-in-force
- 2012-11-21 MY MYPI2014001446A patent/MY165953A/en unknown
- 2012-11-21 US US14/360,095 patent/US20140322315A1/en not_active Abandoned
- 2012-11-21 CA CA2851387A patent/CA2851387A1/en not_active Abandoned
- 2012-11-21 SG SG10201800159QA patent/SG10201800159QA/en unknown
- 2012-11-21 WO PCT/US2012/066288 patent/WO2013078335A1/en not_active Ceased
- 2012-11-21 AU AU2012340670A patent/AU2012340670B2/en not_active Ceased
- 2012-11-21 MX MX2014004469A patent/MX2014004469A/es unknown
- 2012-11-21 KR KR1020147010492A patent/KR20140097132A/ko not_active Ceased
-
2014
- 2014-03-27 ZA ZA2014/02290A patent/ZA201402290B/en unknown
- 2014-05-14 IL IL232608A patent/IL232608A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6214750B2 (ja) | 低用量トピラメート／フェンテルミン組成物およびその使用方法 | |
| JP2014533701A5 (enExample) | ||
| EP3494961B1 (en) | Compositions and methods for treating chronic inflammation and inflammatory diseases | |
| AU2023204000A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| GB2487808A (en) | Oral adjuvant or formulation comprising a lipid and an alcohol | |
| EP2950821A1 (en) | Compositions and methods for treating chronic inflammation and inflammatory diseases | |
| Lutfiya et al. | Molecular docking and interactions between vascular endothelial growth factor (VEGF) receptors and phytochemicals: An in-silico study | |
| WO2023051025A1 (zh) | 白头翁皂苷b4在制备预防或者治疗非酒精性脂肪肝的药物中的应用 | |
| Remy et al. | Repurposing alpelisib, an anti‐cancer drug, for the treatment of severe TIE2‐mutated venous malformations: preliminary pharmacokinetics and pharmacodynamic data | |
| RU2014125282A (ru) | Способы и композиции для лечения воспаления и ишемического поражения | |
| TWI740051B (zh) | 用於治療中風及減少神經損傷的化合物及其用途 | |
| MX2014003256A (es) | Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesion neuronal. | |
| Cai et al. | Ethyl pyruvate improves survival in awake hemorrhage | |
| CN111419800A (zh) | 用于治疗红斑狼疮的药物制剂及其制备方法 | |
| JP2010083871A (ja) | 抗アデノウイルス剤を含有する医薬組成物 | |
| CN105919991A (zh) | 泽兰素在制备治疗抑郁症药物中的应用 | |
| JP2010505827A5 (enExample) | ||
| CN101757019B (zh) | 用于减肥或治疗代谢综合征的药物组合物 | |
| CN109908165B (zh) | 一种含有雷公藤红素的组合物及其应用 | |
| CN109999044B (zh) | 一种含有醉茄素a的组合物及其应用 | |
| CN118236359B (zh) | 硫酸特布他林在防治肠缺血再灌注损伤中的应用 | |
| CN119632984B (zh) | 蝙蝠葛苏林碱在制备髓过氧化物酶抑制剂及治疗急性肺损伤药物中的应用 | |
| CN117137897B (zh) | 索法酮在制备用于预防/治疗银屑病的药物中的应用 | |
| CN104622883B (zh) | 用于治疗动脉粥样硬化的药物制剂及其制备方法 | |
| CN103656639B (zh) | 不规则趋化因子的中和抗体用于制备消除糖尿病心肾功能损害不良代谢记忆的药物的用途 |